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to a series of negative trials that challenged 
therapies previously considered effective (e.g. 
early goal direct therapy, activated protein c, 
steroids), without introducing any new effec-
tive treatments. Mortality for septic shock re-
mains high, achieving 50% and more.2 sepsis 
is a complex syndrome: different types of mi-
croorganisms (e.g. bacteria, fungi) with diverse 
Introduction
the enthusiasm following the publication and implementation of the evidence-based 
guidelines for the management of septic shock1 
faded progressively over the past decade due 
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iNtroDUctioN: sepsis is characterized by a complex immune response. in this study we aimed to provide a review of 
the mechanisms of action of immunoglobulin (ig) related to sepsis and an updated meta-analysis of the clinical effective-
ness of the ig use in septic patients.
eViDeNce acQUisitioN: We performed two separate searches of Medline and other databases with the keywords ig, 
sepsis, septic shock, septicemia, septicemia with no language restrictions in order to review the mechanisms of action of 
igs in sepsis and to update the previous meta-analysis on the effects of the ig therapy on the mortality of adult patients 
with septic shock.
EVIDENCE SYNTHESIS: Pathogens and toxin clearance, anti-inflammatory effects and anti-apoptotic effects on im-
mune cells seems to be the main mechanisms of action of ig therapy in sepsis. the meta-analysis of 18 rcts indi-
cated that the use of intravenous ig reduces the mortality risk of septic patients (odds ratio=0.50 [95% ci 0.34-0.71], 
i2=44.68%). low study quality, heterogeneous dosing regimens and type of ig preparations, and different control inter-
ventions (placebo or albumin) may have influenced our results.
coNclUsioNs: our study showed that the use of intravenous ig therapy in adult septic patients may have a rationale 
and seems to be associated with a reduced mortality. anyway, the treatment effect generally tended to be smaller or less 
consistent if considering only those studies that were deemed adequate on each indicator. so, the available evidence is 
not clearly sufficient to support the widespread use of Ig in the treatment of sepsis.
(Cite this article as: Busani s, Damiani e, cavazzuti i, Donati a, girardis M. intravenous immunoglobulin in septic shock: 
review of the mechanisms of action and meta-analysis of the clinical effectiveness. Minerva anestesiol 2016;82:559-72)
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lar attention to the immunoparalysis phase, 
and performed an updated meta-analysis of the 
clinical effectiveness of the use of iVig during 
sepsis.
Evidence acquisition
A first search of Medline (PubMed) and 
scopus databases from January 2000 to March 
2015 was performed in order to review the 
mechanisms of action of iVig, using the key-
words “immunoglobulins”, “mechanism of ac-
tion” and “sepsis”.
a separate systematic search of the Med-
line (PubMed), scopus, intercollegiate stud-
ies institute (isi) Web of Knowledge and 
cochrane trials register electronic databas-
es was conducted to update soares et al.,7 a 
previous meta-analysis on the clinical effec-
tiveness of iVig in sepsis including studies 
published between 1981 and 2007 (search 
conducted until 2 october 2009). therefore, 
we searched the literature for studies pub-
lished from 2 October 2009 to present (final 
update: 9 February 2015). We included ran-
domized controlled trials (rcts) that evalu-
ated the effects of any standard polyclonal 
iVig or iga-igM-enriched (iggaM) prepa-
rations in adult patients with severe sepsis 
or septic shock, compared with no interven-
tion, placebo or another standard polyclonal 
iVig preparation. the outcome of interest 
was mortality by any cause. the following 
keywords were used: immunoglobulin*, sep-
sis, septic shock, septicemia, septicemia. No 
language restrictions were applied. the fol-
lowing data were extracted from the eligible 
studies using a predefined spreadsheet: date 
recruitment started; publication year; num-
ber of participating centers; mean age and 
baseline severity scores (acute Physiology 
and chronic Health evaluation [aPacHe] 
ii score,8 Simplified Acute Physiology Score 
[saPs] ii,9 sequential organ Failure assess-
ment [soFa],10 sepsis score 11) for treatment 
and control groups; type of iVig (igg or ig-
GAM); daily dose (g/kg day); volume of flu-
id given (ml/kg day); duration of treatment 
(days); total dose (g/kg); type of intervention 
virulence (e.g. endotoxin production) and an-
tibiotic resistances may infect one or more 
body sites in patients with varying comorbidi-
ties and heterogeneous response to infection 
(i.e. hyper-inflammatory, immune-paralysis) 
and treatments. clearly, the standard surviv-
ing sepsis campaign (ssc) approach (early 
eradication of septic foci, antibiotic therapy, 
cardiovascular resuscitation) is life-saving in 
many situations but may not be equally effec-
tive in all patients, particularly in those with 
severe comorbidities and difficult infections. 
New patient-tailored therapies are needed.
in this context, increasing attention was 
focussed upon the immune response to infec-
tion. the host response to an infection con-
sists of a first pro-inflammatory phase, with 
uncontrolled inflammatory cytokine “storm”, 
followed by a protracted anti-inflammatory 
phase, characterized by down-regulation of ac-
tivating cell-surface molecules (e.g. monocyte 
Hla-Dr), t cell “exhaustion” and increased 
immune-cells apoptosis.3 this immunosup-
pressive phase causes a profound dysfunc-
tion of innate/adaptive immune response,4 
and seems to play a major role in patient out-
come (particularly in older patients or with 
pre-existing immune dysfunction). therefore, 
researchers moved their attention from anti-
inflammatory treatments to strategies aimed 
to stimulate the immune system. Despite lim-
ited data in humans, experimental studies on 
different immunomodulatory agents yielded 
encouraging results. Polyclonal intravenous 
immunoglobulins (iVig) with their pleiotrop-
ic effects on the inflammatory and immune 
mechanisms represent a promising therapy to 
modulate both the pro- and anti-inflammatory 
processes.
although the use of iVig in children with 
severe sepsis was supported (grade 2c) in the 
2004 and 2008 ssc guidelines 1-5 and numer-
ous studies indicated a reduction in mortality 
with iVig therapy, the 2012 ssc guidelines 6 
suggested not to use iVig in adult patients with 
severe sepsis or septic shock (grade 2B), as no 
sufficient evidence exists in favour of a benefit.
Herein, we reviewed the rationale for iVig 
in the different phases of sepsis, with particu-
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cells. igs are constituted by heavy (H) and 
light (L) chains and Ig isotypes are classified 
into igg, iga, igM, igD and ige.17 Both H 
and l chains are divided into one variable and 
one constant domain.18 it is well known that 
igs are the major effectors of the humoral im-
mune response, nevertheless, the exact mode 
of action of ig remains largely unexplored. 
if, on the one hand, igs have the role to pro-
tect the host from infection, on the other hand 
they may play a dual antithetical role as pro-
inflammatory or anti-inflammatory agents.19 
it should be emphasized, however, that the 
available information on the mechanisms 
of action of igs mainly derives from animal 
models and have to be translated to human 
physiology.
IgG
igg constant fragment (Fc fragment) plays 
a fundamental role in the pro-inflammatory 
phase in order to counteract an infectious 
event, by acting as an adapter that binds to 
both the innate and adaptive immune sys-
tem.20 However, the innate immunity can be 
activated by igg also through the activation of 
the classical complement pathway or by bind-
ing to FCγR receptors.19 these can be divided 
into high-affinity (FcγRI) and low-affinity 
(FCγRII, FCγRII) receptors. The expression 
of FcγRI is induced by granulocyte-colony 
stimulating factor (G-CSF) and interferon-γ 
(IFN-γ). FCγRII is a collection of 3 proteins a, 
b, c. the “a” form is expressed on monocytes, 
macrophages, dendritic cells, neutrophils and 
platelets. the “b” form is highly expressed on 
B-cells and seems to play an inhibitory effect 
on effector cells. it is also anchored to neutro-
phils and eosinophils. the “c” form is mainly 
expressed on natural killer cells.21 Pincetic et 
al. have recently highlighted a new different 
class of receptors, c-type lectins or “type ii Fc 
receptors” binding the Fc-region of igg.22 all 
these IgG-binding FCγRs promote many cel-
lular pro-inflammatory responses: phagocyto-
sis of opsonised micro-organisms or immune 
complexes, antibody-dependent cellular cy-
totoxicity, activation of NaDPH oxidase and 
in the control group (no treatment or type of 
placebo); baseline risk (control arm log-odds 
for mortality); number of survivors and non-
survivors in each arm and follow-up duration. 
Whenever possible, outcome data were ex-
tracted for the subgroups of patients with se-
vere sepsis or septic shock, separately. Daily 
dose, daily fluid volume given, total dose and 
baseline risk were recoded as “low” or “high” 
based on whether they fell below or above 
the median value of the entire set of studies. 
For the assessment of study quality, we evalu-
ated if concealment of allocation, blinding 
or randomization procedure were adequate/
unclear/inadequate; if an intention-to-treat 
analysis had been performed; if the trial had 
received funding from industry sponsors. a 
Jadad score 12 was calculated for each study. 
A score ≤2 or ≥3 indicated low or high qual-
ity, respectively. Data were synthesized by the 
standard meta-analysis approach, i.e. studies 
were weighted by the inverse of the study 
variance.13, 14 odds ratio (or) was chosen 
as the effect estimate for the data synthesis. 
the Dersimonian and laird random-effects 
model was used as a conservative approach 
to account for different sources of variation 
among studies.13, 14 the results were graphi-
cally represented in forest plots. the i2 mea-
sure and cochrane Q-statistics were used to 
assess heterogeneity.15 Potential sources of 
heterogeneity were explored and the effect 
size (es) was compared between subgroups 
formed by these possible explanatory factors. 
the presence of publication bias was investi-
gated through funnel plots both visually and 
formally by trim and fill analysis and Egg-
ers’s linear regression method.16 a P<0.05 
was used to indicate statistical significance. 
all analyses were conducted using a com-
puter software package (ProMeta2, internovi, 
cesena Fc, italy).
Evidence synthesis
Review of IG mechanisms of action in sepsis
igs are produced and secreted by B-cells 
that are activated and propagated by the t-
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itself. this interaction depends on igM poly-
reactivity, which allows the recognition of 
the invading structures such as nucleic acid, 
phospholipids and carbohydrates.24 like igg, 
igM have receptors for the Fc domain (Fcµr) 
that were only recently identified in humans 
and cats, although their role is still poorly un-
derstood.23 it has not been elucidated yet what 
B-cell subtype is responsible for the produc-
tion of igM antibodies. it seems that different 
B-cell subtypes deriving from the spleen and/
or the peritoneum may play a dominant role 
in different infections. as regards the relation-
ship between igM and B cells, a modulator 
role of igM on the development of B-cells has 
recently emerged. Studies in sIgM-deficient 
mice showed that the deficiency of circulat-
ing igM can lead to a prolonged B-cell sur-
vival. this phenomenon appears to be due to a 
decreased scavenging of circulating antigens 
by igM and enhanced binding to B-cell sur-
face receptors, which induces an increase in 
the intracellular signalling thus favouring cell 
survival.25, 26
the potential roles of ig therapy in sepsis 
have been shown both in experimental and 
clinical studies. in a rabbit endotoxemia mod-
el the infusion of igM-enriched ig exerted a 
protective effect by modulating pulmonary 
proinflammatory host response, as shown by 
a decreased in vitro residual polymorpho-
nuclear neutrophil phagocytosis activity and 
increased in vivo phagocytosis efficiency.27 
similar results were obtained by Nakamura 
et al.28 in cats subjected to splenectomiza-
tion and pneumococcus infection, where ig 
improved survival by increasing phagocyto-
sis in the liver. in an E. Coli-model of sep-
sis in pigs, Barratt-Due et al.29 demonstrated 
that IgM-enriched Ig shifted inflammatory 
response toward an anti-inflammatory profile 
reflected by a significant decrease in the pro-
inflammatory cytokine IL-1β and a significant 
early increase in the anti-inflammatory cyto-
kine il-10. similar results were obtained by 
ates et al.30 in a rat-model of intrabdominal 
sepsis induced by cecal ligation and puncture 
(clP), where rats receiving igM-enriched 
Ig showed lower IL-1β and less histological 
release of cytokines. the main Fc-mediated 
immunomodulatory mechanisms of igg may 
be summarized in: 1) saturation of FCγRs by 
therapy with high-dosage of intravenous igg, 
so that receptors are made unavailable for au-
toantibodies; 2) up regulation of the inhibitory 
FCRγIIb by sialylated IgG Fc; 3) increased 
clearance of pathogenic antibodies; 4) modu-
lation of dendritic cells favouring an anti-
inflammatory response; e) reduced response 
to iFN; 5) inhibition of the complement cas-
cade by sequestrating complement away from 
the deposited autoantibodies.21 in addition to 
the above mentioned Fc domain, igg is com-
posed of a further functional domain known 
as F(ab’)2 fragment that is mainly responsible 
for the antigen recognition. F(ab’)2-dependent 
mechanisms include: killing of target cells by 
antibody-dependent cytotoxicity, blockade of 
cell-cell interactions mediated by cell-surface 
receptors (such as cD95 and cD95 ligand), 
neutralization of cytokines, neutralization of 
autoantibodies by anti-idiotypic antibodies 
and scavenging of anaphylatoxins c3a and 
c5a.21
IgM
igM exists both as a monomer on the sur-
face of B cells and a pentamer secreted by 
plasma cells. Both pre-immune “natural” and 
antigen-induced “immune” igM antibodies 
are important for protective immunity and 
for regulation of the autoimmune processes 
by recognizing pathogens and self-antigens.23 
Pentamer igM is a mushroom-shaped mol-
ecule with a center region binding c1q with 
an affinity 1000-fold higher than that of IgG. 
c1q binds to the Fc fraction of pentameric 
igM and together with mannose binding lec-
tin promotes the phagocytosis of apoptotic 
cells. the ingestion of such apoptotic cells 
promotes the release by the phagocytic cell 
of anti-inflammatory substances such as in-
terleukin 10 and transforming growth fac-
tor.24 one of the characteristics of igM in the 
defence against infections is their ability to 
cause the agglutination of microorganisms 
through direct interaction with the pathogen 
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on multi-resistant gram-positive and gram 
negative bacteria. However, the preparation 
containing igM showed higher killing rates 
against gram-negative bacteria in comparison 
to pure igg preparation. Killing against van-
comycin-resistant S. aureus was significantly 
higher with igM preparation whereas opsonic 
killing against ca-Mrsa, E. faecalis as well 
as E. faecium was higher with igg prepara-
tion.
the main mechanisms of action of ig ther-
apy during sepsis are summarized in Figure 1.
Meta-analysis of IG clinical effectiveness
among the initial 257 records, only one 
study 34 was eligible to update the existing sys-
tematic review. this was included in our meta-
analysis along with the 17 studies identified by 
soares et al.,7 leading to a total of 18 studies 
(Figure 2).34-51
study characteristics are reported in table 
i.34-51 studies were published between 1981 
and 2013; 11 studies (61%) were single-center 
rcts, 7 (39%) were multi-center. the ma-
jority of studies had small sample size, with 
only 2 large rcts involving 682 44 and 624 36 
patients, respectively. There was significant 
damage in the lungs and small intestine than 
the control group. esen et al.31 examined in 
a rat sepsis model clP the effects of ig on 
the blood-brain barrier. they found that sepsis 
induced by clP in animals caused an increase 
in the blood-brain barrier permeability, pre-
dominantly through the transcellular vesicu-
lar pathway. additionally, they demonstrated 
that treatment with intravenous igg and ig 
enriched with iga and igM 5 minutes before 
clP improved the integrity of the blood-brain 
barrier, inhibited clP-induced sickness be-
havior, and reduced the mortality rate of sep-
tic animals. a retrospective clinical study on 
41 patients 32 highlighted that early treatment 
of sepsis-induced coagulopathy using ig in-
travenous therapy significantly improved the 
haemostatic abnormalities and this was attrib-
uted to the ability of high dose of intravenous 
Ig to modulate and inhibit proinflammatory 
cytokine production. an interesting study by 
rossmann et al.33 recently compared the op-
sonic and protective efficacy against multi-
resistant nosocomial pathogens of polyclonal 
standard igg (intraglobin) and igM-enriched 
preparations (pentaglobin). all the tested 
preparations contain opsonic and protective 
antibodies against targets that are present 
Figure 1.—Possible mechanism of action of Ig in the proinflammatory and immunosuppressive phases of sepsis.
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Figure 2.—study selection process.
Table I.—Characteristics of the studies included in the meta-analysis.
study
Date 
recruitment 
start
Partici-
pating 
centers
(N.)
total 
patients
(N.)
type
of ig ig preparation
Duration 
of 
treatment 
(days)
Daily
dose
(g/kg)
Fluid 
volume 
given
(ml/kg 
per day)
total
dose
(g/kg)
type of 
control 
intervention
Mean
age ig/controls, 
years (sD)
severity score
(ig/controls)
Follow-
up
(days)
toth et al.34 2013 2003   1  33 iggaM Pentaglobin (Biotest Pharma, Hungary) 3 0.25 5 0.75 0.9% Nacl 56 (50-65)/60 (50-63)* aPacHe ii 26 (14-35)/25 (15-37)* 28
Behre et al.35 1995 1992   2  52 iggaM Pentaglobin (Biotest Pharma, germany) 3 0.31 6.2 0.93 5% Has 50 (Nr)/55 (Nr) Nr/Nr 28
Burns et al.36 1991 Nr   1  38 igg sandoglobulin (sandoz Pharmaceutical corp italy) 3 0.4 8 1.2 Has 61.5 (Nr)/59.8 (Nr) Nr/Nr  9
Darenberg et al.37 2003 1999  17  21 igg endobulin sD (Baxter) 3 0.667 13.34 2.001 1% Has 51.3 (Nr)/51.6 (Nr) saPs ii, 53 (Nr)/51 (Nr); soFa, 11 (Nr)/11 (Nr) 28
De simone et al.38 1988 1984   1  24 igg sandoglobulin (sandoz Pharmaceutical corp italy) 5 0.2 3.33 1 Nt 45 (4)/45 (5) Nr/Nr 70
Dominioni et al.39 1996 1986   4 113 igg sandoglobulin (sandoz Pharmaceutical corp italy) 5 0.2 4 1 5% Has 55 (19)/57 (19) sepsis score 23 (4)/23 (4) icU-D
grundmann et al.40 1988 Nr   1  46 igg intraglobin F, Biotest Pharma germany 2 0.25 5 0.5 Nt 46.9 (Nr)/52.8 (Nr) Nr/Nr icU-D
Hentrich et al.41 2006 1992   6 206 iggaM Pentaglobin (Biotest Pharma, germany) 3 0.31 6.2 0.93 Has 48.8 (Nr)/ 51.0 (Nr) Nr/Nr 28
Karatzas et al.42 2002 Nr   1  68 iggaM Pentaglobin (Biotest Pharma, germany) 3 0.25 5 0.75 Nt 50.5 (3.3)/50.7 (7.4) aPacHe ii 21.3 (7.2)/23.5 (7.9) 28
lindquist et al.43 1981 1977   1 148 igg Pepsin-treated human gamma globulin - gamma 
venin
3 0.15 3 0.45 Nt 48.3 (Nr)/39.2 (Nr) Nr/Nr 14
Masaoka et al.44 2000 1993 141 682 igg not specified 3 0.07 1.4 0.21 Nt Nr/Nr Nr/Nr 7
rodriguez et al.45 2005 1996   7  56 iggaM Pentaglobin (Biotest Pharma, germany) 5 0.35 7 1.75 5% Has 61.3 (19.9)/65.9 (18.2) aPacHe ii 16.1 (5.9)/15.2 (6.1) icU-D
schedel et al.46 1991 1985   1  55 iggaM Pentaglobin (Biotest Pharma, germany) 3 0.285 5.7 0.855 Nt 46 (16)/37 (18) aPacHe ii 30/24 42
spannbrucker et al.47 1987 Nr   1  50 iggaM Pentaglobin (Biotest Pharma, germany) 3 0.15 3 0.45 Nt 50.8 (15.5)/54.5 (12) Nr/Nr 12
tugrul et al.48 2002 Nr   1  42 iggaM Pentaglobin (Biotest Pharma, germany) 3 0.25 5 0.75 Nt 42 (18)/49.3 (20.6) aPacHe ii 10.5 (4.6)/14 (8.5) 28
Werdan et al.49 2007 1991  23 624 igg Polyglobin N (Bayer Biological Products, 
germany)
2 0.45 9 0.9 0.1% Has 57.2 (13.7)/57.7 (13.6) aPacHe ii 27.6 (4.5)/28 (4.5) 28
Wesoly et al.50 1990 Nr   1  35 iggaM Pentaglobin (Biotest Pharma, germany) 3 0.25 5 0.75 Nt 44.7 (19)/54.8 (17) sepsis score 14.8 (2.5)/16.3 (3.6) icU-D
Yakut et al.51 1998 1992   1  40 igg gamimune N 10% (Miles inc. Pharmaceutical 
Division, Usa)
7 0.26 5.2 1.8 20% Has 32 (16)/31 (16) aPacHe ii 16 (4)/16 (5) 28
Nr: not reported; Nt: no treatment; icU-D: icU discharge; *median (interquartile range).
Total records identified: 
257
Number of articles
included: 1
Duplicates removed:
123
Number
of records screened
(title and abstract):
134
Number of full-text
articles assested
for eligibility:
6
total number of articles
included in the
meta-analysis: 6
Number of full-text
articles excluded: 5
— No rct: 4
—  Mortality non
— reported: 1
Number of articles
included
in soares et al.: 17
heterogeneity across the studies for type of 
ig, dosing regimen, type of control interven-
tion and follow up duration. iggaM were 
used in 9 studies (50%), standard polyclonal 
igg were used in the others. Duration of treat-
ment ranged between 2-7 days, with most of 
the studies using a 3-day treatment (12; 67%). 
average daily dose ranged between 0.07-0.667 
g/kg/day, daily fluid volume given ranged be-
tween 1.4-13.34 ml/kg/day, total dose ranged 
between 0.21-2.001 g/kg. in 8 studies (44%), 
human albumin solution (Has) at varying 
concentrations was used as a control interven-
tion, while no treatment was provided for the 
control arm in 9 rcts; 0.9% Nacl was used in 
one study. Mean age was generally similar be-
tween treatment arms, both within and across 
studies, while severity of illness was variable 
across the studies.
study quality assessment is reported in 
table ii.34-51 concealment of allocation was 
adequate in 6 studies out of 18 (33%), in-
adequate in 2 (11%), unclear in 10 studies 
(55%). Blinding was adequate in 5 studies 
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Table I.—Characteristics of the studies included in the meta-analysis.
study
Date 
recruitment 
start
Partici-
pating 
centers
(N.)
total 
patients
(N.)
type
of ig ig preparation
Duration 
of 
treatment 
(days)
Daily
dose
(g/kg)
Fluid 
volume 
given
(ml/kg 
per day)
total
dose
(g/kg)
type of 
control 
intervention
Mean
age ig/controls, 
years (sD)
severity score
(ig/controls)
Follow-
up
(days)
toth et al.34 2013 2003   1  33 iggaM Pentaglobin (Biotest Pharma, Hungary) 3 0.25 5 0.75 0.9% Nacl 56 (50-65)/60 (50-63)* aPacHe ii 26 (14-35)/25 (15-37)* 28
Behre et al.35 1995 1992   2  52 iggaM Pentaglobin (Biotest Pharma, germany) 3 0.31 6.2 0.93 5% Has 50 (Nr)/55 (Nr) Nr/Nr 28
Burns et al.36 1991 Nr   1  38 igg sandoglobulin (sandoz Pharmaceutical corp italy) 3 0.4 8 1.2 Has 61.5 (Nr)/59.8 (Nr) Nr/Nr  9
Darenberg et al.37 2003 1999  17  21 igg endobulin sD (Baxter) 3 0.667 13.34 2.001 1% Has 51.3 (Nr)/51.6 (Nr) saPs ii, 53 (Nr)/51 (Nr); soFa, 11 (Nr)/11 (Nr) 28
De simone et al.38 1988 1984   1  24 igg sandoglobulin (sandoz Pharmaceutical corp italy) 5 0.2 3.33 1 Nt 45 (4)/45 (5) Nr/Nr 70
Dominioni et al.39 1996 1986   4 113 igg sandoglobulin (sandoz Pharmaceutical corp italy) 5 0.2 4 1 5% Has 55 (19)/57 (19) sepsis score 23 (4)/23 (4) icU-D
grundmann et al.40 1988 Nr   1  46 igg intraglobin F, Biotest Pharma germany 2 0.25 5 0.5 Nt 46.9 (Nr)/52.8 (Nr) Nr/Nr icU-D
Hentrich et al.41 2006 1992   6 206 iggaM Pentaglobin (Biotest Pharma, germany) 3 0.31 6.2 0.93 Has 48.8 (Nr)/ 51.0 (Nr) Nr/Nr 28
Karatzas et al.42 2002 Nr   1  68 iggaM Pentaglobin (Biotest Pharma, germany) 3 0.25 5 0.75 Nt 50.5 (3.3)/50.7 (7.4) aPacHe ii 21.3 (7.2)/23.5 (7.9) 28
lindquist et al.43 1981 1977   1 148 igg Pepsin-treated human gamma globulin - gamma 
venin
3 0.15 3 0.45 Nt 48.3 (Nr)/39.2 (Nr) Nr/Nr 14
Masaoka et al.44 2000 1993 141 682 igg not specified 3 0.07 1.4 0.21 Nt Nr/Nr Nr/Nr 7
rodriguez et al.45 2005 1996   7  56 iggaM Pentaglobin (Biotest Pharma, germany) 5 0.35 7 1.75 5% Has 61.3 (19.9)/65.9 (18.2) aPacHe ii 16.1 (5.9)/15.2 (6.1) icU-D
schedel et al.46 1991 1985   1  55 iggaM Pentaglobin (Biotest Pharma, germany) 3 0.285 5.7 0.855 Nt 46 (16)/37 (18) aPacHe ii 30/24 42
spannbrucker et al.47 1987 Nr   1  50 iggaM Pentaglobin (Biotest Pharma, germany) 3 0.15 3 0.45 Nt 50.8 (15.5)/54.5 (12) Nr/Nr 12
tugrul et al.48 2002 Nr   1  42 iggaM Pentaglobin (Biotest Pharma, germany) 3 0.25 5 0.75 Nt 42 (18)/49.3 (20.6) aPacHe ii 10.5 (4.6)/14 (8.5) 28
Werdan et al.49 2007 1991  23 624 igg Polyglobin N (Bayer Biological Products, 
germany)
2 0.45 9 0.9 0.1% Has 57.2 (13.7)/57.7 (13.6) aPacHe ii 27.6 (4.5)/28 (4.5) 28
Wesoly et al.50 1990 Nr   1  35 iggaM Pentaglobin (Biotest Pharma, germany) 3 0.25 5 0.75 Nt 44.7 (19)/54.8 (17) sepsis score 14.8 (2.5)/16.3 (3.6) icU-D
Yakut et al.51 1998 1992   1  40 igg gamimune N 10% (Miles inc. Pharmaceutical 
Division, Usa)
7 0.26 5.2 1.8 20% Has 32 (16)/31 (16) aPacHe ii 16 (4)/16 (5) 28
Nr: not reported; Nt: no treatment; icU-D: icU discharge; *median (interquartile range).
out of 18 (28%), inadequate in 5 (28%), un-
clear in 8 (44%). randomization procedure 
was adequate in 10 studies (56%), unclear in 
8 (44%). an intention-to-treat analysis was 
performed in 12 studies out of 18 (67%), not 
performed in 4 (22%) and it was unclear for 
the remaining 2 studies. an industry spon-
sorship was acknowledged in 7 studies out 
of 18 (39%), while it was unclear for the re-
maining 9 studies (61%). Four studies (22%) 
achieved a Jadad score of 5, 7 studies (39%) 
scored 3, the remaining 7 studies (39%) 
showed ≤2.
the pooled or (random-effects model) 
was 0.50 (95% confidence interval, 0.34-0.71) 
(P<0.001), indicating a reduction in mortal-
ity with ig as compared with the control arm 
(Has, 0.9% Nacl or no treatment) (Figure 
3).39-51 a moderate heterogeneity was found 
across the studies (i2=44.68%, P=0.022). Fun-
nel plot showed asymmetry (Figure 4), with 
a minor effect however on the es as shown 
by the trim and fill analysis (estimated ES: 
or=0.58 [0.41-0.82], P=0.002).
only a few studies reported numbers of 
patients with severe sepsis or septic shock in 
each arm.35, 38, 41, 45, 49 of these, outcome data 
were reported separately for severe sepsis 
and septic shock subgroups only by Behre et 
al.,35 Hentrich et al.,41 rodriguez et al.45. the 
study by toth et al.34 included only patients 
with septic shock. separate meta-analyses per-
formed for the severe sepsis and septic shock 
subgroups showed similar non-significant ef-
fects (severe sepsis: k=3, N=102, es=0.63 
[0.28-1.40], P=0.260, i2=0%; septic shock: 
k=4, N=241, es=0.82 [0.41-1.64], p=0.580, 
i2=0%).
results of the subgroup analyses are re-
ported in table iii. the type of ig used 
did not influence the ES: IgG and IgGAM 
showed a similar reduction in the odds of 
mortality, although studies using igg gave 
more heterogeneous results. even if the es 
was not significantly affected by differences 
in dosing regimes, a trend towards a greater 
and consistent decrease in mortality was seen 
among studies using lower daily/total dose 
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tended to show a less consistent benefit as 
compared to those using no treatment for 
the control arm. A consistent and significant 
reduction in mortality was seen only among 
studies involving patients with a high base-
line risk for death. the es varied based on 
the duration of follow-up: only those rcts 
and lower daily fluid volume given (Figure 
5a-c, D). studies using a duration of treat-
ment >3 days tended to show a greater re-
duction in the odds of mortality (Figure 5B). 
the es was potentially affected by the type 
of control intervention applied: studies where 
albumin was used as a control intervention 
Table II.—Assessment of study quality.
study concealment of allocation Blinding
randomization
procedure
intention-to-
treat analysis
industry
sponsorship
Jadad
score
toth et al.34 2013 adequate Unclear adequate Unclear Not reported 2
Behre et al.35 1995 Unclear Unclear Unclear Yes Not reported 1
Burns et al.36 1991 Unclear adequate Unclear No Yes 5
Darenberg et al.37 2003 Unclear adequate Unclear Yes Yes 5
De simone et al.38 1988 inadequate inadequate Unclear Yes Not reported 1
Dominioni et al.39 1996 Unclear adequate Unclear No Not reported 3
grundmann et al.40 1988 Unclear Unclear adequate Yes Not reported 2
Hentrich et al.41 2006 adequate inadequate adequate Yes Yes 3
Karatzas et al.42 2002 Unclear Unclear Unclear No Not reported 2
lindquist et al.43 1981 inadequate inadequate Unclear Unclear Not reported 3
Masaoka et al.44 2000 adequate inadequate adequate Yes Yes 3
rodriguez et al.45 2005 adequate adequate adequate Yes Yes 5
schedel et al.46 1991 adequate inadequate adequate No Yes 3
spannbrucker et al.47 1987 Unclear Unclear adequate Yes Not reported 1
tugrul et al.48 2002 Unclear Unclear adequate Yes Not reported 3
Werdan et al.49 2007 adequate adequate adequate Yes Yes 5
Wesoly et al.50 1990 Unclear Unclear adequate Yes Not reported 1
Yakut et al.51 1998 Unclear Unclear Unclear Yes Not reported 3
Figure 3.—Forest plot showing individual and combined es of all the included studies. the size of the boxes is inversely 
proportional to the size of the result study variance, so that more precise studies have larger boxes. the es is expressed as 
odds ratio (OR) and the correspondent 95% confidence interval (CI). An OR below 1.00 (left side of the plot) indicates a 
decreased mortality.
ES: effect size; CI: confidence interval; Sig.: P value.
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reduced survival in patients with severe sep-
sis or pandemic influenza virus (influenza A-
H1N1). the question whether the assessment 
of plasma ig level may be useful for stratifying 
patients who would benefit from replacement 
therapy with iVig remains open. Further stud-
ies on endogenous ig variations during sepsis 
course and their relationship with mortality are 
required.
only one rct evaluating the clinical ef-
fectiveness of iVig therapy was included 
in our analysis to update the previous meta-
analysis by soares et al.34 this was a pilot 
rct on a small cohort of 33 patients with 
septic shock and severe respiratory failure, 
which failed to show any benefit of IgGAM 
therapy on organ dysfunction.34 according 
to previous data, our meta-analysis indicates 
that iVig may reduce mortality in adult pa-
tients with severe sepsis or septic shock. the 
low quality of the rcts analyzed and high 
heterogeneity in the study characteristics (e.g. 
type and dose of ig used, control interven-
tion) hinder significantly the reliability of the 
results observed. in a previous meta-analysis 
by Kreymann et al.,55 a trend in favour of ig-
gaM in comparison with igg was observed. 
in our meta-analysis, ig composition was not 
as a significant source of heterogeneity in the 
subgroup analysis, however studies using ig-
gaM showed a more consistent mortality 
reduction in the treatment arm as compared 
that evaluated icU-mortality showed a signif-
icant reduction in the odds of mortality with 
ig. single-center trials, as well as those with 
unclear concealment of allocation, blinding, 
randomization procedure and industry spon-
sorship, tended to show a greater reduction in 
mortality as compared to multi-center studies 
or those with higher study quality. While old 
studies (published before 2000) showed a re-
duction in mortality, recent studies (published 
from 2000 to present) did not show any sig-
nificant benefit.
Discussion
our review shows that the use of iVig in 
adult patients with severe sepsis and septic 
shock has a consistent rationale and seems to 
be associated with a reduction in the odds of 
mortality, although further studies are needed 
before implementing iVig treatment in sep-
sis.
even if the mechanisms of action are still 
not fully elucidated, basic immunology and 
more recent studies indicate that endogenous 
ig as well as the possible ig supplementa-
tion may play a fundamental role in the host 
inflammatory-immune response to infection. 
Not only ig (particularly igM) can facilitate 
the rapid pathogen and toxin clearance in the 
early phases of infection and modulate the ex-
cessive pro-inflammatory host response, but 
they may be also beneficial in the late phases 
of sepsis characterized by a profound depres-
sion of innate and adaptive immunity. ig exert 
a direct anti-apoptotic effect on lymphocytes 
and facilitate the clearance of apoptotic cells 
by an igM-mediated mechanism that may 
counteract sepsis-induced immune-dysfunc-
tion.24
the assessment of plasma ig levels has been 
proposed for identifying patients at higher 
risk for mortality and who can benefit from 
ig therapy. low igg levels on the day of sep-
sis diagnosis were observed in many clinical 
studies but are inconsistently associated with 
higher mortality.52 recent studies 53, 54 high-
lighted that combined presence of low plasma 
levels of igg1, igM and iga is associated with 
Figure 4.—Funnel plot and trim-and-fill analysis of all the 
included studies. open circles indicate the analyzed studies, 
full circles indicate the trimmed studies.
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Table III.—Subgroup analyses.
k N or [95% ci] P i2 (%) p (between-group comparison)
type of iVig 0.611
igg 9 1736 0.45 [0.24-0.87] 0.018 61.19**
iggaM 9 597 0.55 [0.38-0.81] 0.003 6.66
Dosing regimes
Duration of treatment 0.171
<3 days 2 670 0.65 [0.17-2.47] 0.523 70.61
3 days 12 1430 0.57 [0.39-0.82] 0.002 2.61
>3 days 4 233 0.31 [0.18-0.53] <0.001 0.00
Daily dose 0.203
Low (≤0.25 g/kg) 10 1241 0.39 [0.26-0.58] <0.001 0.00
High (>0.25 g/kg) 8 1092 0.60 [0.35-1.02] 0.058 53.02*
Daily fluid volume given 0.203
Low (≤5 mL/kg) 10 1241 0.39 [0.26-0.58] <0.001 0.00
High (>5 ml/kg) 8 1092 0.60 [0.35-1.02] 0.058 53.02*
total dose 0.312
low (<0.9 g/kg) 9 1159 0.40 [0.25-0.64] <0.001 0.00
High (≥0.9 g/kg) 9 1174 0.57 [0.35-0.93] 0.024 56.59*
type of control intervention 0.199
albumin 8 1150 0.57 [0.34-0.96] 0.035 61.26*
No treatment 9 1150 0.36 [0.22-0.58] <0.001 0.00
0.9% Nacl 1 33 1.25 [0.27-5.83] 0.776 -
Baseline risk 0.043
low 9 1884 0.68 [0.43-1.07] 0.098 37.65
High 9 449 0.36 [0.24-0.54] <0.001 0.00
Follow up duration 0.050
<28 days 4 918 0.50 [0.24-1.07] 0.074 0.00
28 days 8 1086 0.73 [0.49-1.09] 0.124 31.28
>28 days 2 79 0.22 [0.04-1.20] 0.080 34.94
icU-discharge 4 250 0.30 [0.17-0.51] <0.001 0.00
Publication year 0.009
old studies (before 2000) 10 601 0.34 [0.22-0.52] <0.001 0.00
recent studies (from 2000) 8 1732 0.73 [0.50-1.07] 0.110 28.48
study quality
Number of centers 0.483
Multi-center 7 1754 0.55 [0.32-0.93] 0.027 63.09*
single-center 11 579 0.43 [0.27-0.67] <0.001 0.00
concealment of allocation 0.213
adequate 6 1656 0.67 [0.39-1.17] 0.160 54.56
inadequate 2 172 0.58 [0.13-2.53] 0.466 0.00
Unclear 10 505 0.37 [0.25-0.55] <0.001 0.00
Blinding 0.819
adequate 5 852 0.56 [0.25-1.26] 0.163 70.72**
inadequate 5 1115 0.48 [0.21-1.09] 0.079 36.93
Unclear 8 366 0.42 [0.27-0.67] <0.001 0.00
randomization procedure 0.285
adequate 10 1829 0.55 [0.35-0.88] 0.012 49.93*
Unclear 8 504 0.39 [0.24-0.61] <0.001 0.00
intention-to-treat analysis 0.809
Yes 12 1878 0.52 [0.35-0.78] 0.002 41.96
No/unclear 6 455 0.47 [0.23-0.97] 0.040 35.34
industry sponsorship 0.158
Yes 7 1682 0.63 [0.36-1.10] 0.106 52.70*
Not reported 11 651 0.39 [0.27-0.57] <0.001 0.00
Jadad score 0.701
≤2 7 308 0.44 [0.27-0.72] 0.001 0.00
≥3 11 2025 0.51 [0.31-0.84] 0.008 58.43**
K: number of studies; N.: number of particpants; OR: odds ratio; CI: confidence interval.
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that seen among studies using no treatment. 
a biological effect of albumin in the control 
arm may have played a role: the oncotic, car-
rier, antioxidant and anti-inflammatory prop-
erties of albumin are well recognized.56 in 
the alBios study, albumin administration 
was associated with a significant reduction 
in mortality in the subgroup of patients with 
septic shock.56 alternatively, the use of albu-
min could be just an indicator of more appro-
priate blinding, thus being associated with an 
overall higher study quality and lower risk of 
bias.
there are issues with the methodological 
quality of the available evidence. Most of the 
included studies were single-center trials with 
an extremely small sample size, thus being 
underpowered to investigate mortality. Due to 
a publication bias, smaller studies may have 
to those where standard polyclonal igg were 
used. Different dosing regimens and duration 
of treatment appeared to affect the results. 
as discussed in soares et al.,7 it is difficult 
to identify a clinical rationale for these as-
sociations, which should be interpreted with 
caution in light of the high heterogeneity in 
the study characteristics and patients included 
(different severity of shock). Specifically de-
signed dose-ranging studies should clarify the 
potential meaning of these associations. the 
choice of control intervention had a poten-
tial impact on the overall treatment effect. in 
contrast to soares et al.,7 in our meta-analysis 
using a random-effects model a significant 
reduction in mortality with ig was also seen 
when albumin had been administered in the 
control arm, however the effect tended to be 
smaller and less consistent in comparison to 
Figure 5.—random-effects meta-regression analyses showing the relationship between the study effect size and (a) daily 
dose, (B) duration of treatment, (C) volume of fluid administered, (D) total dose. The size of the circles is inversely propor-
tional to the size of the result study variance, so that more precise studies have larger circles.
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of iVig as adjunctive therapy for sepsis. the 
beneficial effect of IVIG tends to be smaller 
or less consistent if considering only high 
quality studies. ideally, a large-scale high-
quality rct would be needed to demonstrate 
a definite survival benefit of IVIG. However, 
as was the case for other treatments, such a 
trial would be unlikely to show any clear ef-
fect on outcome if enrolling a heterogeneous 
population of patients with different basal 
predisposition, varying insult and immune 
response. it may be crucial to individualize 
iVig therapy in terms of type of prepara-
tion, dose and time of administration as a 
function of patient characteristics and sepsis 
course. in this perspective, high quality stud-
ies investigating the true mechanisms of ac-
tion and the clinical effects of different iVig 
preparations in different phases of sepsis are 
required.
Key messages
 — endogenous ig as well as the supple-
mentation of ig may have fundamental role 
in the host inflammatory-immune response 
to infection.
 — ig therapy in patients with sep-
sis may be summarized in increasing the 
pathogens and toxin clearance, direct an-
ti-inflammatory effects mediated via Fcγ 
receptors, inhibition of “upstream media-
tor” gene transcription, inhibition of in-
flammatory “downstream mediator” gene 
transcription, and antiapoptotic effects on 
immune cells.
 — our meta-analysis indicate that ig 
therapy may reduce mortality of adult pa-
tients with severe sepsis or septic shock. 
indeed, the low quality of the rcts ana-
lyzed and the high heterogeneity in the 
study characteristics hinder significantly 
the reliability of the results observed.
 — a large-scale high-quality rct 
would be needed to demonstrate a definite 
survival benefit of Ig treatment, up to then 
a widespread ig use can not be supported as 
adjunctive therapy for sepsis.
 
overestimated the treatment benefit. Only 4 
studies out of 18 showed a Jadad score of 5, 
while 7 studies (39% of total) scored ≤2 (low 
quality). industry sponsorship was not clearly 
specified in more than 60% of the studies. In a 
meta-analysis by alejandria et al.,57 the benefit 
from polyclonal ig was not seen among tri-
als with low risk of bias. in the present meta-
analysis none of the study quality indicators 
was able to explain the heterogeneity per se, 
however the treatment effect generally tended 
to be smaller or less consistent if considering 
only those studies that were deemed adequate 
on each indicator.
Notably, the studies were conducted over a 
wide range of time, during which the manage-
ment of septic patients has changed a lot. in 
the past decade the ssc contributed to stan-
dardize and improve sepsis treatment.58 More 
recent studies published after 2000 failed to 
show a significant survival benefit from IVIG 
treatment, while a reduction in mortality was 
shown by older studies. allegedly, the effect of 
iVig therapy was blunted when administered 
as a part of a more comprehensive and stan-
dardized intervention.
the mortality reduction associated with 
iVig was greater among studies conducted in 
populations with higher baseline risk. Many 
patient-related factors may influence the clini-
cal effect of ig therapy, such as an underlying 
state of immunosuppression, basal levels of 
endogenous igs, time elapsed between sepsis 
diagnosis and ig administration or concurrent 
treatments.53, 59, 60
Unfortunately, it was not possible to analyze 
the iVig-related adverse effects, as these were 
reported only by a small number of the studies 
included. the use of iVig was associated with 
the onset of acute renal failure due to osmotic 
nephrosis in the proximal tubule,61 especially 
with sucrose-stabilized ig preparations.62 a 
specific review should be conducted to clarify 
this point.
Conclusions
There is currently insufficient and low-
quality evidence to support a widespread use 
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